Literature DB >> 15576677

Quantitative detection of siRNA and single-stranded oligonucleotides: relationship between uptake and biological activity of siRNA.

Marita Overhoff1, Winfried Wünsche, Georg Sczakiel.   

Abstract

The quantitative detection of oligomeric nucleic acids including short double-stranded RNA in cells and tissues becomes increasingly important. Here, we describe a method for the detection of siRNA in extracts prepared from mammalian cells, which is based on liquid hybridization with a 32P-labelled probe followed by a nuclease protection step. The limit of detection of absolute amounts of siRNA is in the order of 10-100 amol. This methodology is suited to quantitatively follow the spontaneous uptake of siRNA by mammalian cells, i.e. without the use of carrier substances. This protocol may also be used to detect extremely low amounts of other kinds of short nucleic acids, including antisense oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576677      PMCID: PMC535697          DOI: 10.1093/nar/gnh168

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  14 in total

1.  The effectiveness of double-stranded short inhibitory RNAs (siRNAs) may depend on the method of transfection.

Authors:  D K Walters; D F Jelinek
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2002-12

Review 2.  CpG motifs: the active ingredient in bacterial extracts?

Authors:  Arthur M Krieg
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

3.  The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.

Authors:  Rosel Kretschmer-Kazemi Far; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

Review 4.  Ribozymes: a modern tool in medicine.

Authors:  Asad U Khan; Sunil K Lal
Journal:  J Biomed Sci       Date:  2003 Sep-Oct       Impact factor: 8.410

Review 5.  Emerging clinical applications of RNA.

Authors:  Bruce A Sullenger; Eli Gilboa
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 6.  siRNAs: applications in functional genomics and potential as therapeutics.

Authors:  Yair Dorsett; Thomas Tuschl
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

7.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

8.  The cellular delivery of antisense oligonucleotides and ribozymes.

Authors:  M D. Hughes; M Hussain; Q Nawaz; P Sayyed; S Akhtar
Journal:  Drug Discov Today       Date:  2001-03-01       Impact factor: 7.851

Review 9.  Antisense technologies. Improvement through novel chemical modifications.

Authors:  Jens Kurreck
Journal:  Eur J Biochem       Date:  2003-04

Review 10.  Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.

Authors:  Laixin Wang; Ramesh K Prakash; C A Stein; Richard K Koehn; Duane E Ruffner
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2003
View more
  16 in total

1.  An optimized isolation and labeling platform for accurate microRNA expression profiling.

Authors:  Jaclyn Shingara; Kerri Keiger; Jeffrey Shelton; Walairat Laosinchai-Wolf; Patricia Powers; Richard Conrad; David Brown; Emmanuel Labourier
Journal:  RNA       Date:  2005-07-25       Impact factor: 4.942

2.  Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide.

Authors:  Anke Detzer; Marita Overhoff; Winfried Wünsche; Maria Rompf; John J Turner; Gabriela D Ivanova; Michael J Gait; Georg Sczakiel
Journal:  RNA       Date:  2009-02-18       Impact factor: 4.942

3.  Phosphorothioate-stimulated uptake of short interfering RNA by human cells.

Authors:  Marita Overhoff; Georg Sczakiel
Journal:  EMBO Rep       Date:  2005-12       Impact factor: 8.807

4.  A hexanucleotide selected for increased cellular uptake in cis contains a highly active CpG-motif in human B cells and primary peripheral blood mononuclear cells.

Authors:  Miriam Mende; Anne Hopert; Winfried Wünsche; Marita Overhoff; Anke Detzer; Kirsten Börngen; Peter Schlenke; Holger Kirchner; Georg Sczakiel
Journal:  Immunology       Date:  2006-11-27       Impact factor: 7.397

5.  Modeling RNA interference in mammalian cells.

Authors:  Giulia Cuccato; Athanasios Polynikis; Velia Siciliano; Mafalda Graziano; Mario di Bernardo; Diego di Bernardo
Journal:  BMC Syst Biol       Date:  2011-01-27

6.  Quantification of siRNA using competitive qPCR.

Authors:  Wei-li Liu; Mark Stevenson; Leonard W Seymour; Kerry D Fisher
Journal:  Nucleic Acids Res       Date:  2008-11-12       Impact factor: 16.971

7.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208

Review 8.  Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.

Authors:  S D Laufer; T Restle
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes.

Authors:  Chenguang Zhou; Yue Zhang; Bo Yu; Mitch A Phelps; L James Lee; Robert J Lee
Journal:  Nanomedicine       Date:  2012-10-29       Impact factor: 5.307

10.  DSIR: assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes.

Authors:  Odile Filhol; Delphine Ciais; Christian Lajaunie; Peggy Charbonnier; Nicolas Foveau; Jean-Philippe Vert; Yves Vandenbrouck
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.